BBS Faculty Member - Peter Mundel

Peter Mundel

Department of Medicine

Massachusetts General Hospital
149 13th Street, 8th floor, Room 8.203
Charlestown, MA 02129
Tel: 617-643-8710
Fax: 617-726-5669
Email: mundel.peter@mgh.harvard.edu
Visit my lab page here.



Our laboratory focuses on the development of novel targeted, personalized treatments for proteinuric kidney diseases through a detailed mechanistic understanding of signaling pathways that regulate the function of podocytes in health and disease. In particular, our laboratory studies the actin cytoskeleton, mechanisms of cell survival and metabolic regulation in health and disease, with a specific focus on synaptopodin and Rho GTPase signaling, as well as the role of B7-1/CD80 signaling in podocytes.

Proteinuria is a common feature of kidney dysfunction of glomerular origin and is itself a risk factor for both kidney and cardiovascular disease. The glomerular podocyte is a central component of the kidney filtration barrier. Podocyte injury is typically associated with the development of proteinuria. Specifically, loss of podocytes is a hallmark of progressive injury leading to Chronic Kidney Disease (CKD) and End-Stage Kidney Disease (ESKD), two of the most expensive conditions to treat. And in spite of modern tools and techniques in kidney replacement therapy (dialysis), the 5-year mortality for patients with diabetes requiring dialysis remains at about 70 to 80%, worse than most cancers.
We have just published the first targeted treatment for proteinuric kidney disease in the New England Journal of Medicine. The associated editorial in the NEJM describes our discovery as a “New Era of Podocyte-Targeted Therapy for Proteinuric Kidney Disease.”



Last Update: 11/19/2013



Publications

For a complete listing of publications click here.

 


 

Yu C, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, M.D., Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, and Mundel P. Abatacept in B7-1-Positive Proteinuric Kidney Disease. N Engl J Med. 2013 Nov 8.

Wong JS, Iorns E, Rheault MN, Ward TB, Rashmi P, Weber U, Lippman ME, Faul C, Mlodzik M, Mundel P. Rescue of tropomyosin deficiency in Drosophila and human cancer cells by synaptopodin reveals a role of tropomyosin α in RhoA stabilization. EMBO J. 2012. 15: 1028-1040

Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A. Nat Med. 2008. 14: 931-938



© 2014 by the President and Fellows of Harvard College